We are Main Street
Atlanta

Femasys Adds Marketing Expert to Board of Directors

The appointment signals a strategic move to focus on direct patient demand for the company's fertility portfolio.

Updated on Oct. 30, 2026 in People

Isometric editorial illustration of a sterile medical container, representing a strategic commercial shift in the fertility medical technology sector.
Femasys Inc. has appointed marketing veteran John Moorhead to its Board of Directors as it pivots toward a direct-to-consumer strategy for its fertility portfolio. AI Illustration. Upload story photo >

Live Poll

Do you trust companies to appoint leadership that truly represents the needs of their customers?

Atlanta-based Femasys Inc. has appointed John Moorhead to its Board of Directors following an August 2026 private placement. The appointment signals a shift for the medical device firm as it focuses on direct-to-consumer marketing strategies for its fertility products.

Why it matters

Femasys is prioritizing consumer-facing demand generation for its FemaSeed fertility portfolio, pivoting away from purely clinical sales approaches. By adding a marketing veteran to its board, the company seeks to accelerate patient-led interest in its upcoming fertility solutions.

The appointment of John Moorhead follows 12 years of tenure at Seventh Generation and a recent August 2026 private placement. Femasys continues to advance its FemBloc technology through the FINALE trial while monitoring competitive market entry.

The players

Femasys Inc.

An Atlanta-based medical device developer focused on fertility solutions and advancing its FemBloc technology toward FDA approval.

John Moorhead

A marketing executive formerly with SBM Life Science and Seventh Generation who now serves as a board designee for Femasys.

Dr. Kenneth Eichenbaum

The departing board designee who served in conjunction with the company's November 2025 private placement.

The details

Moorhead arrives as Femasys looks to transition its commercial strategy for the FemaSeed fertility portfolio by increasing direct engagement with OB/GYNs and patients. The board appointment, tied to the company's private placement, underscores a push to secure market adoption for products like FemBloc. This strategy shifts the company's operational focus from purely regulatory approval milestones to broader consumer-marketing integration.

Timeline

  1. November 2025: Dr. Kenneth Eichenbaum began his tenure as a board designee.

  2. 2025: FemBloc received regulatory approvals in Europe, the UK, and New Zealand.

  3. August 2026: The company closed a private placement of its equity.

  4. October 30, 2026: John Moorhead was appointed to the Board of Directors.

Market Landscape

Femasys is aligning its leadership team with the commercial requirements of the FINALE pivotal trial. This follows a broader industry trend where medical device firms appoint consumer marketing experts to drive patient demand ahead of U.S. market entry.

Operators in the medical device sector should monitor how Femasys balances clinical trial progress with these new consumer-marketing expenditures. The company's pivot underscores a need to watch how regulatory-heavy firms effectively translate technical data into patient-led demand.

The takeaway

The appointment signals that Femasys is shifting its operational priority toward consumer brand building to support its fertility product rollout. Business owners should watch for similar moves where medical device firms utilize board-level appointments to pivot toward direct-to-patient marketing strategies.

Further reading

For more background on leadership shifts in local firms, visit the People section.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you trust companies to appoint leadership that truly represents the needs of their customers?